



**Australian Government**  
**Department of Health**  
 Therapeutic Goods Administration

**Public Summary**

<b>Summary for ARTG Entry:</b>	48896	CILICAINE V phenoxymethylpenicillin 125mg/5mL (as benzathine) suspension oral liquid bottle
<b>ARTG entry for</b>	Medicine Registered	
<b>Sponsor</b>	Viatrix Pty Ltd	
<b>Postal Address</b>	Level 1 30 The Bond, 30-34 Hickson Road, Millers Point, NSW, 2000 Australia	
<b>ARTG Start Date</b>	2/05/1994	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Drug Safety Evaluation Branch	

**Conditions**

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

**Products**

**1 . CILICAINE V Oral Suspension 125mg/5mL**

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	3/07/2002
---------------------	-------------------------	-----------------------	-----------

**Permitted Indications**

No Permitted Indications included on Record

**Indication Requirements**

No Indication Requirements included on Record

**Standard Indications**

No Standard Indications included on Record

**Specific Indications**

Treatment of mild to moderately severe infections caused by penicillin sensitive staphylococci, pneumococci, gonococci, and haemolytic streptococci; prevention of bacterial endocarditis in patients with congenital and/or rheumatic heart lesions who are about to undergo dental procedures or minor upper respiratory tract surgery or instrumentation. INDICATIONS AS AT 22 December 1998:When oral therapy is required in the treatment of mild to moderately severe infections due to penicillin sensitive organisms. Therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. For prophylactic use in recent streptococcal infections including the prevention of recurrence following rheumatic fever and/or Sydenham's chorea and to prevent bacterial endocarditis in patients with rheumatic fever and/or congenital heart disease who are about to undergo dental or upper respiratory surgery or instrumentation. Note Oral penicillin should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower intestinal tract surgery, sigmoidoscopy or childbirth.

**Warnings**

See Product Information and Consumer Medicine Information for this product

**Additional Product information**

**Container information**

Type	Material	Life Time	Temperature	Closure	Conditions
Bottle	PP	1 Years	Store at 2 to 8 degrees Celsius	Not recorded	Do not Freeze Refrigerate

**Pack Size/Poison information**

<b>Pack Size</b>	<b>Poison Schedule</b>
100mL	(S4) Prescription Only Medicine

**Components**

**1 . Medicine Component**

<b>Dosage Form</b>	Oral Liquid, suspension
<b>Route of Administration</b>	Oral
<b>Visual Identification</b>	Banana-yellow, uniform, viscous suspension with a banana-like odour and flavour. Free from lumps, gritty particles or visible contamination.

Public Summary



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

**Active Ingredients**

phenoxymethylpenicillin 25.8 mg/mL

**Other Ingredients (Excipients)**

carmellose sodium  
Flavour  
monobasic sodium phosphate  
purified water  
quinoline yellow  
saccharin sodium  
sodium cyclamate  
sodium dehydroacetate  
sorbitol solution (70 per cent) (non-crystallising)

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary